Specifically, we found that BrCa patients with an HSPB2-positive expression status entailed a 2.29-fold higher risk of tumor recurrence as compared to HSPB2-negative ones (HR = 2.29, 95% CI = 1.19–4.42, p = 0.014). This evidence concerns the gene HSPB2 and invasive breast carcinoma.